LDS/Medical Tests/Norfluoxetine, Urine

Norfluoxetine, Urine

Norfluoxetine is one of the Selective Serotonin Reuptake Inhibitors typically known as SSRIs, and belong to the class of drugs known as antidepressants. Norfluoxetine is the most important active metabolite of fluoxetine and exhibits similar pharmacologic effects as fluoxetine. The SSRIs have become the most widely used group of antidepressants in the U.S. The SSRIs typically do not elicit the anticholinergic side effects of the TCAs, are easier to tolerate, and are not as toxic and therefore safer for the patient. The SSRIs are well absorbed and reach peak serum concentrations within 2-12 hours. SSRIs are lipophilic and have large volumes of distribution.

The half-life of norfluoxetine is between 26-220 hours, and thus it takes a long time to achieve steady state concentrations in serum. Many of the therapeutic ranges for these drugs have not been established or there is non-consensus. The effects associated with fluoxetine abuse include hallucinations, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient compliance
A qualitative positive result from an immunoassay type test indicates only the presence of TCAs and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic levels (fluoxetine and norfluoxetine): 120 – 300 ng/mL

Toxic levels: variable

Fatality levels: variable  

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.      

Cut-Off Ranges

Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

 

Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy). This particular method of analysis is used to detect TCAs such as norfluoxetine. Norfluoxetine can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step is required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Specimens should be spun and the serum separated and refrigerated. 

Stability

  • Ambient: 5 days
  • Refrigeration: 7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* COMT and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Antidepressant DEA Drug Fact Sheet
  • Levine B (ed). Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press.,Washington DC. Chapter 14, Therapeutic Drugs II: Antidepressants. 403-420; 2013.
  • Balant-Gorgia AE and Balant LP. Therapeutic drug monitoring of antidepressants. Clin Thera. 1992;14(4):612-4.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.;1996.
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.